Proactive Investors - Run By Investors For Investors

Summit Therapeutics encouraged by performance of C.diff treatment in latest trial

Summit’s drug, Ridinilazole, was more effective than the widely prescribed Vancomycin in preserving the gut microbiome
C-diff is renowned for recurring and often found in hospitals

Summit Therapeutics PLC’s (LON:SUMM) shares jumped on Friday after the firm said its new treatment for superbug C-difficile outperformed the current standard of care in its latest clinical trial.

In the phase II CoDIFy trial, Summit’s drug, Ridinilazole, was more effective than the widely prescribed Vancomycin in preserving the gut microbiome, which is known to be important in protecting both against the initial infection and its recurrence. With this microbiome preservation, ridinilazole treatment resulted in a 59% reduction in recurrence compared to vancomycin (14.3% vs. 34.8%, respectively).”

WATCH: Summit Therapeutics sees a bright future for its antibiotics programmes

Ridinilazole also demonstrated clinical and statistical superiority over vancomycin in sustained clinical response, which measures cure and recurrence over thirty days, said Summit.

"These results show how the precision action of ridinilazole against C. difficile, and its corresponding lack of impact on the broader microbiome, led to greatly increased rates of sustained cures through decreased disease recurrence,” said Dr David Roblin, Summit’s President of R&D.

Better prevention of recurrence is the next frontier in CDI therapy, he added.

"Ridinilazole may have the potential to become new standards of care for serious bacterial infections."

The results from the CoDIFy Phase 2 trial were published in the PLOS One journal.

Summit has received financial backing for the drug from the Biomedical Advanced Research and Development Authority (BARDA) in the US and is eligible to receive up to US$62mln in funding to support the clinical and regulatory development of ridinilazole.

Phase 3 clinical trials are expected to begin in the first quarter of next year.

The UK-listed company is pinning its hopes on ridinilazole after ezutromid, its treatment for muscle wasting disease DMD, failed its most recent clinical trial.

In late morning trading, Summit shares were almost 20% higher at 42.5p.

 -- Adds share price --

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

January 30 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use